Physician profile
Mary E Hoffman
NPI 1386277564
$18,532.32
in general payments reported to CMS, 2019-2025
58 companies · $3,432 in 2025
The $3,432 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,885 · 2022: $2,815 · 2023: $4,208 · 2024: $3,192 · 2025: $3,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,893 · Travel and Lodging: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,893.13 |
| Travel and Lodging | $938.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,367.48 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,439.66 | 2021-2025 | |
| Livanova USA, INC. | $1,313.08 | 2022-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,253.18 | 2021-2025 | |
| Emd Serono, INC. | $773.24 | 2021-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $682.07 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $633.13 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Celgene Corporation | $603.21 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $550.90 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $525.66 | 2021-2025 | Ultomiris, Soliris, Strensiq |
| Banner Life Sciences, LLC | $518.93 | 2023-2024 | |
| Genentech USA, INC. | $468.95 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Eisai INC. | $459.98 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $448.94 | 2021 | |
| Genzyme Corporation | $426.96 | 2021-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $408.07 | 2021-2023 | Ponvory |
| Pfizer INC. | $396.61 | 2023-2025 | |
| Sk Life Science, INC. | $342.96 | 2021-2025 | Xcopri |
| Axsome Therapeutics, INC. | $305.34 | 2022-2025 | Sunosi, Symbravo |
| Lundbeck LLC | $303.88 | 2021-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $265.16 | 2021-2024 | |
| Tg Therapeutics, INC. | $242.74 | 2022-2025 | |
| Amgen INC. | $231.72 | 2021-2025 | Evenity, Prolia |
| Neurelis, INC. | $222.41 | 2021-2025 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $209.01 | 2022 | |
| Argenx US, INC. | $178.77 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $176.35 | 2021-2024 | Inbrija, Ampyra |
| Tersera Therapeutics LLC | $160.05 | 2021-2023 | Quzyttir |
| Radius Health, INC. | $143.67 | 2021-2024 | Tymlos |
| Ucb, INC. | $142.82 | 2022-2024 | Briviact, Nayzilam |
| Amneal Pharmaceuticals LLC | $133.27 | 2022-2025 | Rytary, Brekiya, Lioresal (Baclofen) |
| Takeda Pharmaceuticals U.S.A., INC. | $114.30 | 2025 | Hyqvia |
| Csl Behring | $105.20 | 2021-2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $104.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $83.96 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $78.43 | 2025 | |
| Supernus Pharmaceuticals, INC. | $60.69 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $58.93 | 2023-2024 | Nuplazid |
| Cycle Pharmaceuticals INC | $52.45 | 2025 | Bafiertam |
| Mallinckrodt Hospital Products INC. | $50.22 | 2021-2023 | Acthar |
| Grt US Holding, INC. | $47.66 | 2022 | |
| Sumitomo Pharma America, INC. | $41.41 | 2023 | Aptiom |
| Medtronic, INC. | $36.08 | 2022-2023 | Ascenda |
| Vanda Pharmaceuticals INC. | $34.40 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $34.09 | 2022-2023 | Trudhesa |
| Ani Pharmaceuticals, INC. | $32.65 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $31.53 | 2023 | Nuedexta |
| Merz Pharmaceuticals, LLC | $30.53 | 2021 | |
| Averitas Pharma INC. | $27.16 | 2025 | Qutenza |
| Aucta Pharmaceuticals, INC. | $24.74 | 2025 | Motpoly Xr |
| Scilex Pharmaceuticals INC. | $23.24 | 2025 | |
| Almatica Pharma LLC | $20.87 | 2025 | Loreev Xr |
| Tonix Medicines, INC. | $20.32 | 2025 | Zembrace Symtouch |
| Grifols USA, LLC | $19.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.50 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.48 | 2022 | |
| Sandoz INC. | $17.45 | 2023 | |
| Harmony Biosciences LLC | $15.10 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.